Patrick Keran has joined SeaSpine Holdings Corporation as its first-ever General Counsel, effective October 12, 2015. SeaSpine will surely benefit from Keran’s 15 years of experience as the company currently markets its products in the U.S. and in over 30 countries worldwide.
Patrick Keran: New General Counsel at SeaSpine

“Pat’s business experience gives him a practical, solution-oriented mindset that will serve us well as we position ourselves for growth, ” said Keith Valentine, president and CEO, in the October 20, 2015 news release. “I look forward to Pat’s contributions to building a culture of action and accountability, driving our teams to embrace process simplification, and enabling an ethical, compliant path to our future success.”
As indicated in the news release, “Keran has over 15 years of legal and operational experience, primarily with respect to capital raising, corporate governance and FDA-regulated entities. For the past eight years, Keran has held progressively senior positions at Mast Therapeutics, a clinical-stage drug development company, most recently as president and chief operating officer, where he oversaw multiple acquisitions and raised close to $250 million. Keran will be part of the senior leadership team, reporting directly to Keith Valentine.”
Keran told OTW, “I am excited to join the leadership team of SeaSpine and to contribute to the innovation that will drive growth. I’m looking forward to the opportunity to simplify our operations and approach to the market to make it easier for our surgeon customers and distributors to do business with us.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.